- In January 2025, GSK’s B7-H3-targeted antibody-drug conjugate (GSK227) has received FDA Breakthrough Therapy Designation for the treatment of late-line relapsed or refractory osteosarcoma. This designation will expedite the development and regulatory review process, allowing the treatment to reach the market faster. GSK227 is designed to specifically target cancer cells, providing a more precise and potentially effective approach to treating this aggressive bone cancer. The benefit lies in offering a new treatment option for patients with few alternatives, potentially improving survival rates and quality of life for those suffering from advanced osteosarcoma
- In September 2024, Eli Lilly and Eva Pharma have announced a collaboration to expand access to Baricitinib for low- and middle-income countries. This partnership aims to improve the availability of Baricitinib, an important treatment for autoimmune diseases such as rheumatoid arthritis, in underserved regions. The collaboration will focus on providing more affordable access to the medication, which has shown effectiveness in managing chronic inflammatory conditions. This initiative will benefit patients by ensuring that they have access to a proven treatment, potentially improving their health outcomes and quality of life in areas with limited healthcare resources
- In June 2022, Sirona Biochem and Pfizer have partnered to develop a new treatment for bone diseases. The collaboration focuses on advancing a potential drug designed to address conditions such as osteoporosis and other skeletal disorders. The partnership aims to enhance the development and commercialization of this therapy, leveraging Pfizer's expertise and Sirona's innovative approach. The benefit of this collaboration lies in the creation of more effective treatments for bone diseases, improving patient outcomes by offering alternatives to current therapies. This development could lead to better management of bone health, particularly for aging populations at risk for skeletal complications
